Chemotherapy Induced Nausea & Vomiting
|
|
- Richard Lloyd
- 7 years ago
- Views:
Transcription
1 Chemotherapy Induced Nausea & Vomiting A Nurse s Perspective Michael Flynn MSc, PG Cert, RGN Chemotherapy Nurse Consultant Guy s and St Thomas NHS Foundation Trust
2 Guy s and St Thomas NHS Foundation Trust Two of London s oldest teaching hospitals St Thomas Hospital Waterloo Guy s Hospital London Bridge One of the largest Foundation Trusts in the UK Serving a culturally diverse population with high levels of socioeconomic deprivation. One of five Academic Health Sciences Centres King s Health Partners Guy s and St Thomas NHS Foundation Trust King s College London King s College Hospital NHS Foundation Trust South London and Maudsley NHS Foundation Trust
3 GSTFT Cancer Services Offers a full range of services for the diagnosis treatment and follow up of all adult cancers chemotherapy attendances per annum 6 Linear Accelerators, 4 upgraded Accelerators, Tomotherapy, high dose brachytherapy & Stereotatic body, image guided and inverse planned image modulated radiotherapy Surgery (including laprascopic and robotic assisted surgery offered on day-case and inpatient basis at both hospitals) Hospital & Community Palliative care services A full range of support services including Dimbleby Cancer Care Underpinned by a comprehensive electronic Cancer Information Solution
4 A Quick recap of CINV Definitions Nausea The unpleasant, subjective feeling of the need to vomit Vomiting The forceful release of stomach contents through the mouth caused by strong contractions of the stomach muscles. Woodruff 1997
5 A Quick recap of CINV Physiological Rationale What function do nausea & vomiting perform in the body? Vomiting The physical expulsion of toxins from the stomach. Nausea Trigger for the vomiting reflex. Nausea deterrent from repeat exposure to the toxic substance.
6 Causes of Nausea & Vomiting in Cancer Patients Chemotherapy Uraemia Radiation Concomitant drug treatments Bowel obstruction Gastroparesis: chemo or disease Vestibular dysfunction Anxiety Brain metastases Anticipation Electrolyte imbalance
7 Vomiting pattern generator Also called the vomiting centre Activates the vomiting reflex Located in the medulla area of the brain. Is activated by one or a combination of neuronal pathways.
8 Neuronal Pathways Receptor Ach(M) Cholinergic muscarinic D Dopamine H Histamine NK neurokinin 5HT 5-hydroxytryptamine GABA Gamma-amino butyric acid
9
10 Factors influencing chemotherapy induced emesis Emetogenic risk of chemotherapeutic agent History of motion sickness Gender Performance status Age Other drugs History of alcohol Concomitant medical conditions History of morning sickness
11 Types of CINV Acute onset within 24hrs following chemo administration. Delayed onset after 24hrs following chemo administration. Anticipatory onset before chemo administration. Breakthrough responds to rescue. Refractory doesn t respond to rescue.
12 Emetogenic risk class
13 Principles of Emesis Control The goal is to prevent nausea and/or vomiting. The risk of emesis and nausea for persons receiving chemotherapy of high & moderate emetogenic potential lasts at least 4 days and 3 days respectively. Patients need to be protected throughout the full period of risk. Oral and IV antiemetic formulations have equivalent efficacy NCCN 2009
14 Principles of Emesis Control The toxicity of the specific antiemetic(s) should be considered. Antiemetic regimens should be chosen based on the drug with the highest emetic risk in the chemotherapy regimen, previous experience with antiemetics, and patient-specific risk factors. NCCN 2009
15 Present GSTFT Antiemetic Prophylaxis Emetogenic risk group High (>90%) Moderate (30-90%) Acute Nausea & vomiting prophylaxis (0 to 24 hours after chemotherapy) Aprepitant 125mg PO stat Ondansetron 16mg PO stat Dexamethasone 8mg PO stat Ondansetron 8mg PO stat Dexamethasone 8mg PO stat Delayed Nausea & Vomiting prophylaxis (24 or more hours after chemotherapy) Aprepitant 80mg PO days 2&3 Ondansetron 16mg PO stat day 2 Dexamethasone 8mg PO OD 3/7 Metoclopramide 20mg PO TDS 3/7 Dexamethasone 8mg PO OD 3/7 Metoclopramide 20mg PO TDS 3/7
16 Surely therefore since the development of 5HT3 receptor antagonists the problem is sorted. Just attach the correct antiemetic prophylaxis to the chemotherapy regime and the patient will be protected.
17 Not Quite
18 Chemotherapy induced nausea and vomiting Most feared side effect Hawkins (2009) Consistently list chemotherapy induced nausea and vomiting as one of their greatest fears...continues to have a great impact on the quality of life. Hesketh (2008) Rice (2011)
19 Current incidence of CINV Approximately 70 to 80% of all cancer patients receiving chemotherapy experience nausea and/or vomiting. 10 to 44% experience anticipatory nausea and/or vomiting.
20 Audit planning Plan to audit 50 patients Patients would be receiving Cisplatin based therapy. Cisplatin known to cause acute and delayed CINV. Audit would cover both nausea & vomiting. Although anecdotal reports of vomiting were the primary reason for auditing, it was expected that nausea would be the major issue. Questionnaire based on the MASCC designed tool. Vomiting objective number of times Acute Delayed Nausea subjective rating from 1 to 10 Pretreatment Acute Delayed
21 Audit Results n=73 Gender Age Diagnosis Male 30 <40 3 Upper GI 17 Female Gynae 17 Undisclosed Head & Neck 14 >59 38 Lung 4 Undisclosed 4 Melanoma 2 Liver 2 Colorectal 2 Undisclosed 15
22 Audit Results
23 Audit Results Findings of note Acute Nausea (AN) n=37 Median onset 12 hours Median patient subjective rating 5 Delayed Nausea (DN) n= 38 Median onset Day 2 Median patient subjective rating 5 DN without experiencing AN n=8 Median onset Day 2 Median patient subjective rating 4.5
24 Audit Results Diagnosis Number Pre% AV% AN% DV% DN% Upper GI Gynae Head & Neck Age & Gender showed no significant differences in any reported field Presence of delayed vomiting without acute vomiting suggests duration of prophylaxis not adequate at present. Diagnosis may contribute to a disposition to nausea however treatment intensity and anatomical factors are more likely.
25 Audit findings interpretation Patient Nausea is an expected and accepted side effect of treatment This has led to an underreporting of nausea to healthcare professionals during the treatment phase. Anticipatory nausea is a real threat to patients receiving treatment 2 nd line prophylaxis escalation is not consistent or sustained and unlikely to be successful Delayed vomiting suggests either under treatment or delay in prophylaxis commencement Delayed vomiting prophylaxis is not adequate and needs to be targeted to high risk groups
26 Audit findings interpretation Organisational Process Assessment of Nausea & Vomiting Present lack of structure coordination and communication of proactive assessment between outpatient clinics and treatment units. Lack of consistent approach to 1 st line prophylaxis utilisation of out of date paper proformas and failure to adjust proformas to current guidelines suggest lack of knowledge of and access to current guidelines. Inconsistent approach to 2 nd line prophylaxis Suggestive of lack of knowledge of and access to current guidelines.
27 Recommendations based on Audit for HEC* Increase Dexamethasone dose to 12mg. Include PPI coverage in prophylaxis Use Aprepitant 1 st line in patients classified as high risk. Use Palonosetron as 5HT3 receptor antagonist of choice in patients receiving multiple day regimes
28 Re-evaluation of CINV MASCC inspired questionnaire re-used Audit group all patients receiving HEC and MEC regimes Target to audit 100 patients
29 What changed between 2009 and 2012? All patients receiving HEC regimes receive Aprepitant first line. Complete e-prescribing and electronic medical record. Pre treatment consultations delivered in a clinic structure by competency assessed nurses. Pro-active telephone monitoring 24hrs after 1 st treatment episode. Tumour specific chemotherapy link nurses Nurse led Acute oncology assessment unit with telephone triage 0830 to 1830hrs (Oncall medical service out of hours)
30 CINV related calls to AOAU Month Calls Month Calls June October July November August December September January
31 Audit was expected to show significant improvement in CINV occurrence and intensity
32 Not Quite
33 CINV Audit 2012 compared with 2009 Year Pre Nausea % Acute Vomiting % Acute Nausea % Delayed Vomiting % Delayed Nausea % Total Nausea %
34 CINV Audit 2012 compared with 2009 Median 5 Median 4.5 Year Pre Nausea % Acute Vomiting % Acute Nausea % Delayed Vomiting % Delayed Nausea % Total Nausea % Median 4 Median 4.5
35 CINV Audit 2012 compared with 2009 Median 5 Median 4.5 Year Pre Nausea % Acute Vomiting % Acute Nausea % Delayed Vomiting % Delayed Nausea % Total Nausea % (13) 9(4) 33(39) 9(13) 45(48) 51(61) Median 4 (5) Median 4.5(6)
36 Pre-chemotherapy CINV Assessment 80 clinic entries for patients receiving HEC and MEC regimes week commencing 10 th of September Entries CINV grading of previous cycle 10 Grade 0 6 Grade 1 1/6 prophylaxis adjusted 5 Grade 2 4/5 prophylaxis adjusted 1 Grade 3 1/1 prophylaxis adjusted 4 Entries document Nil other toxicity 54 Entries nausea assessment not documented
37 What does it all mean? Patients expect to feel nauseated? Is CINV really preventable in all patients? We expect patients to feel nauseated? There is an acceptable level of nausea for different regimens? We continue to underestimate the effect of CINV on patients? Patients don t or can t contact us when they feel nauseated? A blanket pharmacological solution is not the answer?
38 Way forward - GSTFT Joint working project with Pharma understanding the significance of other risk factors apart from agent emetogenic risk. Continue development of the pre-treatment consultation in regards to assessment of CINV risk. Continued development of pre-treatment consultation effectiveness in regards to access of acute oncology services. Expansion of proactive telephone monitoring for patients identified as high risk. Development of a prophylaxis kit for moderate emetogenic risk patients. Further development of multiprofessional chemotherapy on treat clinics.
Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults
Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults Protocol Code Tumour group Physician Contact SCNAUSEA SUPPORTIVE CARE Dr. Paul Hoskins ELIGIBILITY Adults receiving
More informationNausea and Vomiting. Understanding nausea and vomiting. What causes nausea and vomiting in people with cancer?
Nausea and Vomiting Understanding nausea and vomiting Nausea is a subjective unpleasant feeling in the back of your throat and stomach that may lead to vomiting. There are many words that describe nausea
More informationNURSING RESEARCH IMPORTANT POINTS COMPONENTS COMPONENTS. Proposed timeline Consent/ protection of human
NURSING RESEARCH Implementation of a Chemotherapy-Induced Nausea and Vomiting Clinical Pathway for Moderate-high to Highly Emetogenic Chemotherapies A Nursing Research Project 2/01/2014 3/31/2015 PURPOSE:
More informationGuidelines for the Management of. Nausea and Vomiting in Cancer Patients
Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes
More informationTexas Medicaid/CHIP Vendor Drug Program Drug Utilization Criteria For Outpatient Use Guidelines
About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationDelayed emesis: moderately emetogenic chemotherapy
Support Care Cancer (2005) 13:104 108 DOI 10.1007/s00520-004-0700-8 R E V I E W A R T I C L E Fausto Roila David Warr Rebecca A. Clark-Snow Maurizio Tonato Richard J. Gralla Lawrence H. Einhorn Jorn Herrstedt
More information11. CANCER PAIN AND PALLIATION. Jennifer Reifel, M.D.
11. CANCER PAIN AND PALLIATION Jennifer Reifel, M.D. While supportive care was not one of the original clinical areas selected for the development of quality indicators, the Oncology and HIV Panel felt
More informationApplying the Principles of Antiemetic Therapy to the Management of CINV: A Case-study Approach
Applying the Principles of Antiemetic Therapy to the Management of CINV: A Case-study Approach Applying the Principles of Antiemetic Therapy to the Management of CINV: A Case-study Approach Program Agenda
More informationPatient Electronic Alert to Key-worker System (PEAKS) Guidelines
Patient Electronic Alert to Key-worker System (PEAKS) Guidelines This procedural document supersedes: PAT/EC 4 v.1 Guidelines for Patient Electronic Alert to Key-worker systems (PEAKS). Did you print this
More informationMASCC/ESMO Antiemetic Guideline 2013
MASCC/ESMO Antiemetic Guideline 2013 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD Jørn Herrstedt,
More informationPublished Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614. J Clin Oncol 29. 2011 by American Society of Clinical Oncology
Published Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.4614 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C
More informationLung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma
More informationKING KHALID UNIVERSITY HOSPITAL PHARMACY TEAM
KING KHALID UNIVERSITY HOSPITAL PHARMACY TEAM MINUTES OF THE MEETING Month: 29 th September Location: Director of Pharmacy office Date/Time : 29-09-2012 (13-11-1433H) 12.30pm to 2.30pm Chairman of the
More informationMeasure #430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination Therapy National Quality Strategy Domain: Patient Safety
Measure #430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination Therapy National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION:
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationOptimizing Care for the Individual with Cancer: Counseling Patients and Families on Cancer Treatment
Optimizing Care for the Individual with Cancer: Counseling Patients and Families on Cancer Treatment Rowena Schwartz, Pharm.D., BCOP Evaluating Care Opportunities HB is a 57 year old male with newly diagnosed
More informationThe N Factor: Prevention & Treatment of Chemotherapy-Induced Nausea & Vomiting
The N Factor: Prevention & Treatment of Chemotherapy-Induced Nausea & Vomiting 45 TH ANNUAL GREAT LAKES CANCER NURSING CONFERENCE SOMERSET INN, TROY, MICHIGAN OCTOBER 2012 JOANNE P. MCGURN, BS PHARM, BCOP
More informationCancer Survival - How Long Do People Survive?
A research briefing paper by Macmillan Cancer Support Introduction Key findings 3 People with cancer are surviving longer 4 Median survival time has seen dramatic improvement for some cancers 5 Median
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More information5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)
5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol) Indication: Adjuvant Chemo-radiotherapy for patients with resectable adenocarcinoma of the stomach
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationPRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including
More informationCancer treatment and diabetes
Cancer treatment and diabetes Dr Daniel Morganstein Consultant Endocrinologist, 1 2 Diabetes and cancer Cancer and its treatment also poses challenges to managing diabetes Surgery Altered appetite Cachexia
More informationWest of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)
West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility
More informationPain and Symptom Management in the Pancreatic Cancer Patient. Objectives:
Pain and Symptom Management in the Pancreatic Cancer Patient Michael D. Harrington, M.D. Division of Geriatrics and Palliative Care MetroHealth Medical Center April 25, 2012 Objectives: Understand palliative
More informationLambeth and Southwark Action on Malnutrition Project (LAMP) Dr Liz Weekes Project Lead Guy s & St Thomas NHS Foundation Trust
Lambeth and Southwark Action on Malnutrition Project (LAMP) Dr Liz Weekes Project Lead Guy s & St Thomas NHS Foundation Trust Page 0 What is the problem? Page 1 3 million (5 % population) at risk of malnutrition
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationCompany Update. February 8, 2016
Company Update February 8, 2016 Legal Disclaimer This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements
More informationThe Role of the MDT Coordinator. Laura Throssell
The Role of the MDT Coordinator Laura Throssell NHS Cancer Plan (2000) the care of all patients with cancer should be formally reviewed by a specialist team. all patients have the benefit of the range
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationParkinson s Disease: Factsheet
Parkinson s Disease: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Parkinson s disease (PD) is a progressive neuro-degenerative condition that affects a person s
More informationCLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline 1.1. Systemic cancer treatments and immunological therapies can suppress the ability of the bone
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationGuidance on competencies for management of Cancer Pain in adults
Guidance on competencies for management of Cancer Pain in adults Endorsed by: Contents Introduction A: Core competencies for practitioners in Pain Medicine B: Competencies for practitioners in Pain Medicine
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationBasic Radiation Therapy Terms
Basic Radiation Therapy Terms accelerated radiation: radiation schedule in which the total dose is given over a shorter period of time. (Compare to hyperfractionated radiation.) adjuvant therapy (add-joo-vunt):
More informationObjectives. Mechanism-Based Therapy. The Approach to Nausea, Vomiting, and Pain at The End of Life
The Approach to Nausea, Vomiting, and Pain at The End of Life Thomas R. DeGregory D.O. CMD Hospice and Palliative Care Assessment Pathophysiology Treatment Objectives Mechanism-Based Therapy 1. Determine
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationCollaborative Care Plan for PAIN
1. Pain Assessment *Patient s own description of pain is the most reliable indicator for pain assessment. Pain intensity to be assessed using the ESAS (Edmonton Symptom Assessment Scale) Use 5 th Vital
More informationDIABETIC ENTEROPATHY: TWO. Gary L. Cornette, D.O., F.A.C.O.I Medical Director Gastroenterology
DIABETIC ENTEROPATHY: TWO DIFFICULT PROBLEMS DIAGNOSIS AND TREATMENT Gary L. Cornette, D.O., F.A.C.O.I Medical Director Gastroenterology Diabetic Enteropathy: What is it? Motility Disorders Esophageal
More informationAims of Nutritional Support in Oncology (Parenteral) Part 2
Aims of Nutritional Support in Oncology (Parenteral) Part 2 Rachel Barrett MSc, BSc (Hons) RD Principal Haematology-Oncology Dietitian Hong Kong Hospital Authority Commissioned Training November 20 th
More informationTo provide the Board with the current position and new standards issued in June 2011.
Agenda Item: From: 6a Tonia Dawson (Nurse Director) BOARD REPORT E-Prescribing Update 1 Purpose To provide the Board with the current position and new standards issued in June 2011. 2 Background In June
More informationMetastatic Melanoma What You Need to Know
ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationCOST OF SKIN CANCER IN ENGLAND MORRIS, S., COX, B., AND BOSANQUET, N.
ISSN 1744-6783 COST OF SKIN CANCER IN ENGLAND MORRIS, S., COX, B., AND BOSANQUET, N. Tanaka Business School Discussion Papers: TBS/DP05/39 London: Tanaka Business School, 2005 1 Cost of skin cancer in
More informationMedical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA
THE UNIVERSITY OF BRITISH COLUMBIA Department of Urologic Sciences Faculty of Medicine Gordon & Leslie Diamond Health Care Centre Level 6, 2775 Laurel Street Vancouver, BC, Canada V5Z 1M9 Tel: (604) 875-4301
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationESPEN Congress Florence 2008
ESPEN Congress Florence 2008 Nutritional consequences of cancer therapy Nutritional support and monitoring during chemoand radiotherapy M. Larsson (Sweden) Nutritional consequences of cancer therapy Nutritional
More informationThe Effectiveness Of Online Learning In Supporting Nurses Across Ontario To Obtain Their National Certification. de Souza Institute August 29, 2012
The Effectiveness Of Online Learning In Supporting Nurses Across Ontario To Obtain Their National Certification de Souza Institute August 29, 2012 Content development Laura Rashleigh led all four years
More informationYour Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
More informationCoping With Nausea and Vomiting From Chemotherapy
NAUSEA AND VOMITING Coping With Nausea and Vomiting From Chemotherapy Presented by Richard J. Gralla, MD Multinational Association of Supportive Care in Cancer Steven M. Grunberg, MD The University of
More informationNovartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)
Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf
More informationCANCER TREATMENT: Chemotherapy
CANCER TREATMENT: Chemotherapy Chemotherapy, often called chemo, is the use of drugs to treat a disease. The term chemotherapy is now most often used to describe a type of cancer treatment. Dr. Khuri:
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More informationDocetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer
Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient
More information03/20/12. Recognize the right of patients to appropriate assessment and management of pain
Narcotic Bowel Syndrome Alvin Zfass M.D. M.D. Professor of Medicine Toufic Kachaamy M.D. GI Fellow Chronic Pain 110 million Americans suffer from chronic pain according to the NIH Cost of untreated t or
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationAlcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
More informationOVARIAN CANCER TREATMENT
OVARIAN CANCER TREATMENT Cancer Care Pathways Directorate Tailored Information in Cancer Care (TICC) Sir Anthony Mamo Oncology Centre National Cancer Plan May 2015 Contents About this booklet 1 The Ovaries
More informationThe Cancer Patient Journey. Dr. Jaco Fourie
The Cancer Patient Journey Dr. Jaco Fourie The Cancer Patient Journey Prevention and health promotion Screening Diagnosis and staging Treatment Surveillance and survivorship End of life care The Cancer
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationGuidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
More informationAntiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Produced by Pinkie Chambers and Susanna Daniels University College Hospital NHS Foundation Trust November 2010 (Review date
More informationImproving Cancer Pain Relief through a dedicated, Hospice-based Interventional Pain Service.
Improving Cancer Pain Relief through a dedicated, Hospice-based Interventional Pain Service. John Browne, Consultant Pain Specialist, Catherine McGonagle, Frances O Driscoll, Pain Relief Nurse Specialists,
More informationS A N D R A C U E L L A R
S A N D R A C U E L L A R Professional Experience January 2006-Present September 2003-Present September 2003-Present Director, Oncology Specialty Residency University of Illinois at Chicago Medical Center
More informationUse of Guidelines for Treatment of Stage 3 Colon Cancer
Use of Guidelines for Treatment of Stage 3 Colon Cancer Most stage 3 colon cancer patients receiving chemotherapy at a cancer centre after surgery are treated according to the provincial guideline. Some
More informationI will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?
What is node-positive breast cancer? Node-positive breast cancer means that cancer cells from the tumour in the breast have been found in the lymph nodes (sometimes called glands ) in the armpit area.
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationYour A-Z of coping with nausea and vomiting A guide for patients and their carers. We care, we discover, we teach
Your A-Z of coping with nausea and vomiting A guide for patients and their carers We care, we discover, we teach Contents What is this guide about?.... 1 What causes nausea and vomiting?... 1 Some common
More informationOncology Medical Home Measure Specification Data
Oncology Medical Home Measure Specification Data Measure Name Chemotherapy pathway compliance Measure # 1 Measure Description % of chemotherapy treatments that have adhered to NCCN guidelines or pathways.
More informationThe CCG Assurance Framework: 2014/15 Operational Guidance. Delivery Dashboard Technical Appendix DRAFT
The CCG Assurance Framework: 2014/15 Operational Guidance Delivery Dashboard Technical Appendix DRAFT 1 NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information Nursing
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationOncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care
Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care John Fox, MD MHA Senior Medical Director Priority Health 1 Cancer Care is the Leading Edge of Medical Cost Trend for
More informationAdvancing Health Economics, Services, Policy and Ethics. Reka Pataky, MSc ARCC Conference May 25, 2015
Advancing Health Economics, Services, Policy and Ethics Reka Pataky, MSc ARCC Conference May 25, 2015 Acknowledgements: Ontario Team: Dr. Murray Krahn (PI) Dr. Claire de Oliveira Karen Bremner Dr. Kelvin
More informationSymptom Based Alcohol Withdrawal Treatment
Symptom Based Alcohol Withdrawal Treatment -Small Rural Hospital- Presenter CDR Dwight Humpherys, DO dwight.humpherys@ihs.gov Idaho State University Baccalaureate Nursing Program Lake Erie College of Osteopathic
More informationAwareness of the inappropriate use of GI prophylaxis and its cost. Adverse effects of proton pump inhibitor
Understand the indication for stress ulcer/gi prophylaxis Awareness of the inappropriate use of GI prophylaxis and its cost Adverse effects of proton pump inhibitor A. 65yo w/ HTN and ESRD on HD p/w left
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationPalliative Radiation. Dr. G. Schroeder
Palliative Radiation Dr. G. Schroeder Indications for Palliative Radiation Pain Control Bone Metastases Pressure of tumour on nerves Relief of Superior Vena Obstruction Spinal Cord Compression Bleeding
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationAdvancing Nursing Expertise in the Care of Older Patients with Cancer: A Multidisciplinary Educational Course for Oncology Nurses
Advancing Nursing Expertise in the Care of Older Patients with Cancer: A Multidisciplinary Educational Course for Oncology Nurses Heidi Yulico RN, MSN, GNP-BC Lorraine McEvoy DNP, MSN, RN, OCN Beatriz
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationVITAMIN D PRODUCTS -WHAT AND WHEN TO PRESCRIBE. Claudette Allerdyce Principal Pharmacist Croydon CCG Pharmacy Team
VITAMIN D PRODUCTS -WHAT AND WHEN TO PRESCRIBE Claudette Allerdyce Principal Pharmacist Croydon CCG Pharmacy Team WHAT ARE THE ISSUES? A lack of suitable licensed vitamin D products in the UK for treating
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPreventing and Treating Nausea and Vomiting Caused by Cancer Treatment
A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationLidocaine Infusion for Perioperative Pain Management. Marley Linder, PharmD Matt McEvoy, MD
Lidocaine Infusion for Perioperative Pain Management Marley Linder, PharmD Matt McEvoy, MD Perioperative Surgical Home: PCS Shared Goals Improved Outcomes (pain, PONV, LOS, SSI) Improve Throughput (Clinic
More informationHeadaches in Children
Children s s Hospital Headaches in Children Manikum Moodley, MD, FRCP Section of Pediatric Neurology The Cleveland Clinic Foundation Introduction Headaches are common in children Most headaches are benign
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationCancer in Ireland 2013: Annual report of the National Cancer Registry
Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationHow To Get A Tirf
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More information